Bank Of America Corp Biomarin Pharmaceutical Inc Call Options Transaction History

Bank Of America Corp

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$74.43 - $92.22 $20.2 Million - $25 Million	-271,400 Reduced 83.25%	54,600 $4.5 Million
Q1 2024 May 15, 2024	BUY	$83.81 - $99.0 $24.5 Million - $28.9 Million	292,000 Added 858.82%	326,000 $28.5 Million
Q4 2023 Feb 14, 2024	BUY	$76.22 - $98.51 $769,822 - $994,951	10,100 Added 42.26%	34,000 $3.28 Million
Q2 2023 Aug 14, 2023	SELL	$86.68 - $100.3 $7.53 Million - $8.72 Million	-86,900 Reduced 78.43%	23,900 $2.07 Million
Q1 2023 May 12, 2023	BUY	$87.74 - $117.27 $3.11 Million - $4.16 Million	35,500 Added 47.14%	110,800 $10.8 Million
Q3 2022 Nov 14, 2022	BUY	$82.16 - $96.94 $3.9 Million - $4.6 Million	47,500 Added 170.86%	75,300 $6.38 Million
Q2 2022 Aug 12, 2022	BUY	$71.48 - $86.85 $1.87 Million - $2.27 Million	26,100 Added 1535.29%	27,800 $2.3 Million
Q4 2021 Feb 08, 2022	BUY	$71.72 - $91.47 $14,344 - $18,294	200 Added 13.33%	1,700 $150,000
Q2 2021 Sep 13, 2021	BUY	$75.51 - $84.79 $113,265 - $127,185	1,500 New	1,500 $125,000

631

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $15.8B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.